spacer
home > ebr > Autumn 2010
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2010
   
Text
PDF
BioBusiness, Finance & Communication
Trish Meek at Thermo Fisher Scientific and Dennis Fallen at Fisher BioServices discuss the importance of informatics tools in the translational science process, highlighting laboratory information management systems as an ideal solution for more effective collaboration.  
view
download pdf
Translational medicine is a new term for an old approach that has again become relevant to contemporary issues. However, its true value lies in the seamless integration of the public and commercial sector, explains Bob Damms and Ian Rhodes at PA Consulting Group.  
view
download pdf
As the opportunities for conducting trials in developing countries increases, Gary Muddyman at Conversis weighs up the risks and challenges involved in working in these countries given their unique cultures and little understanding of Western medical concepts.  
view
download pdf
bullet
BioResearch and Innovation
David Koos, Steven F Josephs and Ewa Carrier at Entest BioMedical, and Thomas E Ichim at Medistem Inc, look at the approaches being used to target the main cause of cancer: the tumour stem cell.  
view
download pdf
Reporting on the recent developments of anti-tumour immune response studies, Karl-Hermann Schlingensiepen at Antisense Pharma GmbH presents potential treatments emerging from a combination of traditional approaches.  
view
download pdf
Within the opening decade of the 21st century, biological products as therapeutics have taken their place in the ranks of the top 10 global pharmaceutical drugs. Consultant Emile Bellott looks at the impact this market growth has had worldwide.  
view
download pdf
bullet
Discovery Technology
The ability of RNA interference – the pathway through which protein synthesis can be blocked – to silence disease-causing genes effectively has placed it as one of the most promising technologies driving the future of the pharmaceutical market. Balasubramanyam Nistla at GBI Research looks at the technology’s potential in cancer care.  
view
download pdf
Manfred Gossen at BCRT, Berlin describes how Tet technology can facilitate the translation of scientific advancement into medical progress, giving examples in diabetes and cancer, and its vast innovative potential in advancing pharmacological and biomedical research.  
view
download pdf
Gregory V Goldmacher at ICON Medical Imaging makes the case for a centralised approach versus local readers when determining a subject’s suitability for a clinical trial, citing robust statistical results and cost savings as key benefits of using this method.  
view
download pdf
In contrast to the ‘one drug, one target’ model, recent approaches to reprofiling have revealed that many drugs act on more than one target. Daniel Auerbach, Lukas Baumann and Mandana Rezwan at Dualsystems Biotech look at the variety of technologies available for target identification and how this can be used to reposition marketed drugs to alternative indications.  
view
download pdf
bullet
BioDevelopment and Regulatory
Adaptive trial designs are the most cost-effective, efficient way to get the best out of a clinical trial endeavour, argues Shein-Chung Chow at Duke University School of Medicine, in his review of the range of different options available to today’s trial organisers.  
view
download pdf
As always, speed is of the essence in drug discovery, and methodologies that streamline the research process are very welcome. Ulf Landegren at Uppsala University shows how biomarker technologies are up to the challenge.  
view
download pdf
As the marketplace becomes more competitive, the technological demands of the research process can often become too great for individual CROs. Samantha James of Simbec Research introduces the idea of centralised laboratory services, which can offer the specialist skills required for the task.  
view
download pdf
bullet
BioFormulation and Manufacturing
While regulatory authorities are introducing guidelines to take biopharma through the 21st century, Hedley Rees at Biotech PharmaFlow argues that the problem of modernisation stems not from regulations, but from the management culture within the industry.  
view
download pdf
The integrity of data quality is fundamental to any research project; Diane Meakin and Janette Waterhouse at R5 Pharmaceuticals provide ways in which confidence in data can be controlled and improved.  
view
download pdf
Chris Ullman of Isogenica Ltd gives a detailed analysis of how phage display methods can assist the discovery process in a variety of ways, especially when it comes to finding new molecules for protein and peptide-based therapeutics.  
view
download pdf
bullet
BioRegional
As pharmaceutical investment in the Kingdom of Saudi Arabia continues to grow, Rani Abraham at ClinTec International details the challenges, regulations and cultural aspects that need to be considered.  
view
download pdf

Although still in its early growth phase, Satya Dash at the Association of Biotechnology Led Enterprises explains why the future of India’s presence in the global biotechnology market is dependent on the political landscape and government support.

 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

BioIVT Webinar Will Discuss How to Optimize Microbiome Research

BioIVT, a leading provider of research models and services for drug development, today announced that it is hosting a webinar entitled “The Microbiome: Understanding Why Collection and Processing Matters” at 11 a.m. ET on July 25.
More info >>

White Papers

Bringing more control to temperature-sensitive logistics

UPS Supply Chain Solutions

By 2016, world sales of cold-chain drugs and biologics such as vaccines and blood plasma products will near $240 billion1. The increase has led to a surge in discussion about how to protect these products throughout the transportation logistics cycle. Industry experts are recommending that the term “cold chain” be eliminated from rules, guidance and best-practice documents. “Cold chain” now includes a broader spectrum of temperature ranges, such as controlled room temperature (CRT). This white paper focuses on the initial steps required to establish a temperature-sensitive supply chain.
More info >>

Industry Events

Drug Discovery 2018

9-10 October 2018, ExCeL Arena, London, UK

ELRIG’s flagship conference, Drug Discovery, has become the largest meeting of life sciences industry professionals in the UK. Now in its 12th year, Drug Discovery 2018 will take place in London’s Excel Arena. This 2-day event will bring together more than 1200 delegates and over 100 exhibiting companies from around the world who will highlight the latest ground-breaking research, discuss cutting-edge advances in the application of laboratory technology to understand disease biology and to identify novel chemical and biological candidate drugs.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement